Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
Community
/
India
/
Pharmaceuticals & Biotech
Create a narrative
Pharmaceuticals & Biotech Indian Community
Our community narratives are driven by numbers and valuation.
Create a narrative
All companies
Popular
Undervalued
Overvalued
Pharmaceuticals & Biotech Indian Investing Ideas
Indoco Remedies
TH
ThewealthyinvestorbyDSAB
Community Contributor
Indoco Remedies Will Benefit from India's Healthcare Growth
Indoco Remedies presents a compelling investment opportunity due to its balanced business model, focusing on both domestic strength and international expansion. The company is well-positioned to benefit from: India’s growing healthcare ecosystem , driven by higher spending, population growth, and rising disease burden.
View narrative
₹380.00
FV
15.3% undervalued
intrinsic discount
-6.53%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
7
users have followed this narrative
6 months ago
author updated this narrative
Indegene
AN
AnalystConsensusTarget
Consensus Narrative from 6 Analysts
M&A And Cortex Integration Will Expand Enterprise Opportunities
Key Takeaways M&A activities and AI integration signal innovation and efficiency, likely boosting topline growth and improving net margins through cost reductions. Strengthening pharma partnerships and strategic acquisitions are poised to enhance revenue, earnings, and shareholder value by expanding capabilities and cost-effectiveness.
View narrative
₹644.67
FV
13.7% undervalued
intrinsic discount
12.47%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
6
users have followed this narrative
1 day ago
author updated this narrative
Gland Pharma
AN
AnalystConsensusTarget
Consensus Narrative from 13 Analysts
Launch Of 13 New Molecules Will Expand Product Portfolio
Key Takeaways Expansion in the U.S. market through new product launches and collaborations is set to boost revenue and strengthen market penetration. Strategic focus on high-value complex products and biologics aims to enhance long-term earnings and profitability.
View narrative
₹1.77k
FV
13.7% overvalued
intrinsic discount
13.00%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
7
users have followed this narrative
Updated
narrative
Aarti Drugs
AN
AnalystConsensusTarget
Consensus Narrative from 1 Analyst
USFDA And MHRA Approvals Will Unlock New Global Markets
Key Takeaways Entry into regulated foreign markets and new capacity expansions will boost exports, revenue growth, and profit margins while leveraging rising global healthcare demand. Backward integration, sustainability initiatives, and China+1 advantages will reinforce cost efficiency, supply stability, and improve competitiveness and ESG standing.
View narrative
₹628.00
FV
14.3% undervalued
intrinsic discount
14.41%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
2
users have followed this narrative
Updated
narrative
Glenmark Pharmaceuticals
AN
AnalystConsensusTarget
Consensus Narrative from 11 Analysts
Upcoming Diabetes And Respiratory Launches To Expand Product Portfolio
Key Takeaways Growth in India's formulations, notably in dermatology and cardiac, and upcoming diabetes product launches are set to drive future revenue growth. Strategic partnerships and regulatory filings in oncology and respiratory sectors aim to bolster global position and revenue growth.
View narrative
₹2.06k
FV
4.0% overvalued
intrinsic discount
10.92%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
4
users have followed this narrative
Updated
narrative
Caplin Point Laboratories
AN
AnalystConsensusTarget
Consensus Narrative from 2 Analysts
Expansion Into Latin America And US Injectables Will Strengthen Future Prospects
Key Takeaways Expanding into Latin America and the U.S. market aims to drive significant revenue growth through international expansion and front-end presence. Investments in manufacturing and complex product development could enhance production capacity and improve margins through increased efficiencies.
View narrative
₹2.51k
FV
16.2% undervalued
intrinsic discount
16.58%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
7
users have followed this narrative
1 day ago
author updated this narrative
Eris Lifesciences
AN
AnalystConsensusTarget
Consensus Narrative from 10 Analysts
Semaglutide Launch Will Secure Early Position In India's GLP-1 Market
Key Takeaways Strategic GLP-1 market entry and Bhopal facility ramp-up are expected to boost revenue and margins through innovation and operational efficiency. Cost structure optimization and debt reduction enhance financial leverage, improving net and EBITDA margins while reducing interest expenses.
View narrative
₹1.71k
FV
4.6% overvalued
intrinsic discount
14.94%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
3
users have followed this narrative
1 day ago
author updated this narrative
Tarsons Products
AN
AnalystConsensusTarget
Consensus Narrative from 5 Analysts
Automation And New Products Will Create Future Opportunities
Key Takeaways The ramp-up of the Panchla facility and focus on automation are set to enhance production capacity, improve operating margins, and drive profitability. Expansion into international markets and new product lines in healthcare could significantly increase revenue growth and broaden the customer base.
View narrative
₹571.40
FV
33.0% undervalued
intrinsic discount
14.75%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
10
users have followed this narrative
1 day ago
author updated this narrative
Neuland Laboratories
AN
AnalystConsensusTarget
Consensus Narrative from 2 Analysts
Enhancing Peptide Capacity Will Tap Into Expanding Market For Peptide Therapies
Key Takeaways Strategic investments in capital expenditure and peptide capacity aim to boost future revenues, profitability, and operational margins. Focus on high-value and complex chemistry positions Neuland for higher-margin opportunities and revenue growth from FY '26 onwards.
View narrative
₹16.01k
FV
13.8% undervalued
intrinsic discount
24.57%
Revenue growth p.a.
Set Fair Value
1
users have liked this narrative
0
users have commented on this narrative
3
users have followed this narrative
1 day ago
author updated this narrative
Value any company in seconds
Popular companies